Merck & Co., Inc., a leading global healthcare company, has filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on March 19, 2024. The registration statement pertains to the issuance of debt securities, which may be offered and sold from time to time by Merck. The company has appointed U.S. Bank Trust National Association as the trustee for the debt securities. The registration statement includes a prospectus that provides detailed information about the debt securities, including their potential form, terms, and conditions. Merck & Co. has also outlined the plan of distribution for the debt securities, which may involve underwriters, dealers, agents, or direct sales to investors. The company has made provisions for indemnification of directors and officers, and...Show More

Merck & Co., Inc., a leading global healthcare company, has filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on March 19, 2024. The registration statement pertains to the issuance of debt securities, which may be offered and sold from time to time by Merck. The company has appointed U.S. Bank Trust National Association as the trustee for the debt securities. The registration statement includes a prospectus that provides detailed information about the debt securities, including their potential form, terms, and conditions. Merck & Co. has also outlined the plan of distribution for the debt securities, which may involve underwriters, dealers, agents, or direct sales to investors. The company has made provisions for indemnification of directors and officers, and the registration statement includes the necessary legal opinions and consents. The debt securities will be a new issue with no established trading market prior to their issuance, and Merck & Co. may choose to list the securities on an exchange. The registration statement also includes undertakings by Merck & Co. to provide updates and post-effective amendments as required by the SEC.